Literature DB >> 25446297

Novel markers and therapies for patients with acute heart failure and renal dysfunction.

Peter A McCullough1, John L Jefferies2.   

Abstract

BACKGROUND: Acute kidney injury complicates decompensated heart failure in ∼33% of cases and is associated with morbidity and mortality; thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches.
METHODS: Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis, and 58 were included.
RESULTS: Acute kidney injury, defined by substantial increases in serum creatinine, is associated consistently with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter- and longer-term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function.
CONCLUSIONS: The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Biomarker; Clinical outcomes; Systematic review

Mesh:

Substances:

Year:  2014        PMID: 25446297     DOI: 10.1016/j.amjmed.2014.10.035

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure.

Authors:  Junjie Xiao; Rongrong Gao; Yihua Bei; Qiulian Zhou; Yanli Zhou; Haifeng Zhang; Mengchao Jin; Siqi Wei; Kai Wang; Xuejuan Xu; Wenming Yao; Dongjie Xu; Fang Zhou; Jingfa Jiang; Xinli Li; Saumya Das
Journal:  Cell Physiol Biochem       Date:  2017-02-16

2.  The Japanese Clinical Practice Guideline for acute kidney injury 2016.

Authors:  Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada
Journal:  J Intensive Care       Date:  2018-08-13

Review 3.  The Japanese clinical practice guideline for acute kidney injury 2016.

Authors:  Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2018-10       Impact factor: 2.801

4.  Relaxin Attenuates Contrast-Induced Human Proximal Tubular Epithelial Cell Apoptosis by Activation of the PI3K/Akt Signaling Pathway In Vitro.

Authors:  Xiang-Cheng Xie; Yizhi Cao; Xiu Yang; Qun-Hong Xu; Wei Wei; Ming Wang
Journal:  Biomed Res Int       Date:  2017-04-30       Impact factor: 3.411

5.  Combination of Amino-Terminal Pro- BNP , Estimated GFR , and High-Sensitivity CRP for Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients.

Authors:  De-Qiang Zhang; Hong-Wei Li; Hai-Ping Chen; Qing Ma; Hui Chen; Yun-Li Xing; Xue-Qiao Zhao
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.